

Application No.: 10/581,577
Filing Date: June 2, 2006

REMARKS

Claims 1-10 have been cancelled as directed to non-elected subject matter. Applicant reserves the right to pursue this subject matter in one or more divisional applications. The claims have been amended as discussed further below and to correct clerical error and improve clarity. No new matter is added.

Priority

This paper includes an amendment to the specification to recite the International Application No. and priority applications in the first paragraph on page 1 of the specification.

Double patenting

Claims 11, 12, and 19 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-8 of copending Application No. 10/581,568.

Applicant respectfully requests that the provisional double patenting rejection be held in abeyance until allowable subject matter is indicated.

Rejection under 35 U.S.C. § 112, second paragraph

Claims 14 and 17 are rejected under 35 U.S.C. § 112, second paragraph as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 14 and 17 are rejected for depending from non-elected claims 1 and 9. The dependency of claim 14 has been amended to depend from claim 11; the dependency of claim 17 has been amended to depend from claim 16.

In view of Applicant's amendments, withdrawal of the rejection is respectfully requested.

Rejection under 35 U.S.C. § 102(e)

Claims 11, 12, 15, and 17 are rejected under 35 U.S.C. § 102(e) as being anticipated by Evans, et al.

This ground of rejection is addressed by amendment.

Application No.: 10/581,577
Filing Date: June 2, 2006

Claim 11 has been amended to specify a method for treating cancer in which the platelet releasate is administered “to the patient in need of cancer treatment”.

As clarified by Jansen v. Rexall Sundown 342 F3d 1329 (Fed. Cir. 2003), the phrase “in need of” must be given patentable weight. In the present case, the method is performed on a person in need of cancer treatment. Evans, et al. does not relate to cancer treatment at all. Accordingly, Evans, et al. do not teach all of the elements of the claimed invention.

Claims 12 and 15 depend from claim 11. Claim 17 has been amended to depend from claim 16 which relates to a method of treating cancer.

In view of Applicant’s amendments and arguments, reconsideration and withdrawal of the rejection is respectfully requested.

Rejection under 35 U.S.C. § 103(a)

Claims 11-20 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Evans, et al. (US 2003/0236573) as applied to claims 11, 12, 15 and 17 above and further in view of Gordinier, et al. (US 5,599,558) and further in view of Ozek, et al. (Journal of Burn Care and Rehabilitation, pp. 65-69, January/February 2001).

As discussed above, all of the claims have been amended to relate to a method of treating cancer by administering formulations containing platelet releasate to cancer patients in need thereof.

None of the references cited by the Examiner teach treatment of cancer. However, Gordinier, et al. teach topical treatment of chronic wounds and Ozek, et al. is cited for teaching that chronically ulcerating wounds change into cancer. The Examiner posits that these references taken together would indicate a reasonable expectation of success for the treatment of cancer with platelet releasate.

In response, it is very counterintuitive to treat cancer with platelet releasate because platelet releasate contains components such as growth factors known to stimulate the growth of cancer cells. See for example the attached article by Cromie (Attachment A) which discusses higher cancer risk for individuals with higher growth factor levels and Rajkumar (Attachment B) which teaches that while growth factors play a role in wound healing (see Abstract), unregulated

expression of growth factors may lead to malignant transformation (page 535, col. 2, last line). Accordingly, Rajkumar makes a distinction between a wound and a cancer.

While Gordinier, et al. teach treatment of wounds with platelet releasate, Gordinier, et al. do NOT teach treatment of cancerous wounds with platelet releasate. The disclosure of Ozek, et al. is limited to 5 case studies for chronically ulcerating wounds after burn injuries in which the cells had differentiated into squamous cell carcinoma. However, not all chronic wounds show neoplastic changes and there is nothing in the combination of references which would lead one of ordinary skill in the art to apply platelet releasate to cancer cells as a treatment. Indeed, the art would teach away from administration of platelet releasate to cancer cells as platelets are known to contain growth factors and increased levels of growth factors are associated with cancer.

Furthermore, none of the cited references teach the method steps of claims 19 and 20 in which bone marrow cells are cultured with platelet releasate and then administered to the patient in need of cancer treatment.

The Office Action refers to columns 15 and 16 of Gordinier, et al. as teaching cell culture. However, cols. 15-16 (Example 11) merely describes a method of assaying for ECCA (endothelial cell chemotaxis activity) which is a platelet releasate activity as described in col. 12, lines 20-29. Gordinier, et al. taken alone or in combination with the other references, do not teach culture of cells from the patient with platelet releasate and reinjection of the cells back into the patient in need of cancer treatment.

In view of Applicant's amendments and arguments, reconsideration and withdrawal of the above ground of rejection is respectfully requested.

No Disclaimers or Disavowals

Although the present communication may include alterations to the application or claims, or characterizations of claim scope or referenced art, Applicant is not conceding in this application that previously pending claims are not patentable over the cited references. Rather, any alterations or characterizations are being made to facilitate expeditious prosecution of this application. Applicant reserves the right to pursue at a later date any previously pending or other broader or narrower claims that capture any subject matter supported by the present disclosure, including subject matter found to be specifically disclaimed herein or by any prior prosecution.

Application No.: 10/581,577
Filing Date: June 2, 2006

Accordingly, reviewers of this or any parent, child or related prosecution history shall not reasonably infer that Applicant has made any disclaimers or disavowals of any subject matter supported by the present application.

Co-Pending Applications of Assignee

Applicant wishes to draw the Examiner's attention to the following co-pending applications of the present application's assignee.

Docket No.	Serial No.	Title	Filed
MISHRA.006C1DV1	11/777968	COMPOSITIONS AND MINIMALLY INVASIVE METHODS FOR TREATING INCOMPLETE TISSUE REPAIR	13-Jul-2007
MISHRA.012DV1	12/265232	PARTICLE/CELL SEPARATION DEVICE AND COMPOSITIONS	05-Nov-2008
MISHRA.022NP	10/581568	METHOD OF CULTURING CELLS	02-Jun-2006

CONCLUSION

In view of Applicants' amendments to the claims and the foregoing Remarks, it is respectfully submitted that the present application is in condition for allowance. Should the Examiner have any remaining concerns which might prevent the prompt allowance of the application, the Examiner is respectfully invited to contact the undersigned at the telephone number appearing below.


Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 2, 2009

By:


Che Swyden Chereskin, Ph.D.
Registration No. 41,466
Agent of Record
Customer No. 20,995
(949) 721-6385

April 22, 1999

the
HARVARD
UNIVERSITY

Gazette

HARVARD GAZETTE ARCHIVES

contents
notes
newsmakers
police log

Gazette home
Gazette archives
Harvard News Office
Feedback

SEARCH THE
GAZETTE

search

Growth Factor Raises Cancer Risk

By William J. Cromie
Gazette Staff

High levels of a well-known growth factor significantly increase the risks of colorectal, breast, and prostate cancer, medical researchers have found.



Edward Giovannucci (left), Jing Ma, and their colleagues have linked high levels of a natural growth factor to colorectal, breast, and prostate cancer. Photo by Kris Snibbe.

At the same time, they determined that a protein that binds to the growth factor seems to neutralize it and reduce the risk of these malignancies, which are three of the four biggest cancer killers in the United States.

"If further studies confirm these findings, blood levels of the growth factor and its binding protein might be used to identify people at the highest risk for these cancers and, therefore, who might benefit most from lifestyle changes and other means of prevention," says Jing Ma, an instructor in medicine at Harvard Medical School. Also, future work on the binding protein could lead to new drugs for treating colorectal, breast, and prostate tumors in their earliest stages.

The growth factor, known as insulin-like growth factor-1, or IGF-1, is necessary for proper growth in children, but studies of men and women more than 40 years old raise the possibility that it contributes to the growth of tumors. These studies were conducted at Channing Laboratory in Boston, a joint facility of Harvard Medical School and Brigham and Women's Hospital in Boston, and at the Harvard School of Public Health.

Last week, the researchers announced that, in a six-year study of 32,826 nurses, those with the highest levels of IGF-1 had a

two-and-a-half times greater risk of colorectal cancer. High levels of IGF binding protein-3 (IGFBP-3) produced the opposite effect.

The week before, another group from the same laboratory reported in the *Journal of the National Cancer Institute* that a study of 14,916 male physicians concluded that men run the same risk. In the case of those with the highest IGF-1 and lowest IGFBP-3, the relative risk of colorectal cancer rose fourfold, after accounting for differences in weight, height, alcohol intake, and other known risk factors.

"The fact that these two large studies give the same results for both men and women increases our confidence in the findings," notes Edward Giovannucci, an assistant professor of medicine who led the nurses' study. Giovannucci is also assistant professor in the Department of Nutrition at the Harvard School of Public Health.

Last year, data from the investigation of male physicians also showed that men with the highest levels of IGF-1 had more than four times the risk of prostate cancer than those with the lowest levels.

Another Channing Laboratory team concluded that premenopausal women with high IGF-1 levels have more than double the relative risk of breast cancer. Younger women are at greatest risk. This team was led by Susan Hankinson, an assistant professor of epidemiology at the School of Public Health and an assistant professor of medicine at the Medical School.

In all these studies, blood samples were collected from 32,826 nurses and 14,916 physicians between 1982 and 1990. None of these people had cancer at the time. They were then followed by questionnaires for 6 to 14 years. Those who developed cancer were then matched by age and smoking frequency with those who stayed cancer-free, and their blood levels of IGF-1 and IGFBP-3 were compared.

Slowing Aging

These results raise concern about attempts to slow aging in older people by giving them growth hormone to increase their IGF-1. Since levels of both substances decrease with age, some observers suggest that injections of the hormone may counter several effects of getting old.

In one study, 12 men, 61 to 81 years old, were given growth hormone three times a week. After six months, their blood

showed levels of growth hormone similar to those in men 10 to 20 years younger. They achieved increases in muscle mass and skin thickness and decreases in body fat compared to a matched group who didn't take the hormone.

A subsequent study of 27 women, 62 to 82 years old, who took the hormone showed a decrease in fat and some protection against bone loss.

These results caused a torrent of media reports suggesting that science had found away to stall, even reverse, some degenerative changes of aging.

"We would advise healthy people not to take the hormone," Ma says. "Our studies raise concern that giving it over long periods will increase the risk of prostate and colorectal cancers." Other researchers have found a lack of gain in muscle strength and physical performance despite the increase in muscle mass and decrease in fat.

"We've not shown directly that the hormone is harmful," Giovannucci adds. "Potentially, there could be some benefit from giving it to people with a growth-hormone deficiency. But people should understand that there's a risk involved, and proceed cautiously."

Too Much Growth

"There's good biological rationale for the associations we found," Giovannucci says. When IGF-1 is added to dishes of cells growing in the laboratory, the cells flourish like flowers blooming in spring. In children, the hormone stimulates bone growth and development of organs such as the heart, liver, and kidneys. But in older people, rapidly proliferating cells increase the opportunity for genetic mutations that may lead to cancer. And once cancer cells begin to form, IGF-1 will promote their growth as well as that of normal cells.

Ma mentions evidence of a connection between colorectal cancer and acromegaly, a condition that causes enlargement of facial features, hands, and feet due to excess secretion of growth hormone. "The rate of colorectal cancer among acromegalics is abnormally high, because their IGF-1 levels can be up to 10-fold higher than those of normal people," she notes.

"The levels of IGF-1 implicated in increased risks for cancer among middle-aged and older nurses and physicians in our studies are not as high as those in acromegalics or abnormally tall people," Giovannucci explains. "Rather they are at the

high end of what we would consider a normal range."

IGF-1 is a major determinant of height, and taller people are at higher risk for colorectal, breast, and prostate cancer, according to Ma. "It is possible that people who grow tall, because of higher levels of IGF-1 in childhood and adolescence, have a high risk of cancer in adulthood," Giovannucci points out. "However, someone who retains high levels of the hormone from childhood through middle age might be at even higher risk."

Levels of IGF-1 drop when people eat less. Animal studies show that decreases in food intake lessen tumor growth and increase life span, Ma and Giovannucci agree. "However, it's too early to make specific recommendations about restricting calories on the basis of our results," Ma cautions.

It's also too early to determine if a test based on blood levels of IGF-1 and IGFBP-3 will predict who will get colorectal, prostate, or breast cancer. The findings of the Harvard researchers must be confirmed by additional large studies.

Meanwhile, drug companies and other research teams are exploring the feasibility of designing new cancer drugs based on the activity of IGF-1 and IGFBP-3.

Giovannucci, Ma, and their colleagues are now investigating the role of diet, physical activity, alcohol consumption, and other possible determinants of high IGF-1 and low IGFBP-3 levels. "It might be possible to adjust these levels and lower cancer risks with lifestyle changes that are not too drastic," Ma speculates.

"We're also looking at genes that might control levels of the growth factor and its binding protein," notes Giovannucci. "People found to possess a genetic predisposition to IGF-1-related cancers could be closely monitored and, perhaps, pretreated with lifestyle changes and new drugs."



Copyright 1999 President and Fellows of Harvard College

Growth factors and growth factor receptors in cancer

T. Rajkumar

Department of Molecular Oncology, Cancer Institute (WIA), Adyar, Chennai 600 020, India

Growth factors and growth factor receptors play a major role in growth and development, wound healing and have many physiological functions. Derangement in the function of these molecules plays an important role in cancer. This paper reviews the role of growth factors and their receptors in cancer, particularly, the members of the tyrosine kinase receptor family.

It is well known that multi-cellular organisms evolved from unicellular ancestors. In the less complex unicellular organisms the key functions of finding food, responding to changes in the environment (external temperature and pH changes) and the stimuli for cell division are mediated by chemical changes within the same cell (Figure 1). However, in a multi-cellular organism the different functions needed to sustain the life of the organism are carried out by different organs. As most of the vital functions require the participation of more than one organ it becomes necessary to develop a system to communicate and co-ordinate events between cells of the same and different organs. The cells in a multi-cellular organism have achieved this by developing a wide array of receptors on their surface to which specific ligands bind and induce specific responses.

Growth factors and growth factor receptors

Growth factors (GF) and growth factor receptors (GFR) play an important physiological role in the normal process of growth and differentiation. In a simplistic model, the binding of the growth factor to its receptor leads to receptor dimerization and cross phosphorylation, activating the receptors. The activated receptors phosphorylate a series of cytoplasmic proteins which in turn sets off a cascade of events leading to the activation of transcription factors in the nucleus, which then leads to increased mRNA synthesis. The translation of the mRNA results in increased protein synthesis finally leading to either growth or differentiation¹.

The peptide and polypeptide growth factors, unlike classical hormones, are produced in a variety of tissues throughout the body and their action is not necessarily

restricted to single tissue types. These factors can act by an intracrine, autocrine, juxtacrine, paracrine or endocrine process (Figure 2). Autocrine action is due to the secretion by a cell of growth factors (transforming growth factor α (TGF α) and epidermal growth factor (EGF)) for which it possesses receptors, (epidermal growth factor receptor (EGFR))^{2,3}. Some experiments have suggested that this interaction may even occur within a cell, a process called intracrine interaction⁴. Juxtacrine stimulation is when one cell has surface bound growth factors which interact with an adjacent cell containing receptors for the growth factor (TGF α)⁵. Paracrine action is defined as the release by cells, of soluble growth factors which diffuse into the extracellular space and act upon adjacent or closely located cells. In the case of endocrine action, growth factors are carried in the blood stream and may act on distant sites much like a classical hormone.

Aberrations in the growth factor signalling pathways can lead to abnormal growth and development. Loss of function mutations in growth factor receptors can lead to inherited diseases such as insulin-resistant diabetes (insulin receptor)⁶ and dwarfism (Achondroplasia) (Fibroblast growth factor receptor 3 (FGFR3 receptor))⁷. Overexpression of growth factors can lead to non-neoplastic disorders like psoriasis (TGF α)⁸. Cancer is now recognized to be the result of a multistep process^{9,10}. Among the events that can lead to malignant transformation is the unregulated expression of growth factors or components of their signalling pathways.




Figure 1.

e-mail: cancer_institute_wia@vsnl.com

Tyrosine kinases

Although a cell may respond to a vast number of growth factors and possess a variety of types of receptors, there are only a few known intracellular second messenger systems through which all these signals can be channelled into the cytoplasm and then into the nucleus. These are the cyclic AMP and the cyclic GMP systems, control of free intracellular calcium levels, usually mediated by the action of inositol 1,4,5-triphosphate, the pathways involving receptor protein tyrosine kinases and the tumour growth factor β (TGF β) which utilizes receptor serine/threonine kinases. The activation of tyrosine kinases may be linked to a mechanism for increasing the free intracellular calcium levels (activation of phospholipase C γ leads to hydrolysis of phosphatidylinositol 4,5-bisphosphate to inositol triphosphate which in turn results in the elevation of free calcium levels).

The tyrosine kinases can be classified into receptor tyrosine kinases, cytoplasmic non-receptor tyrosine kinases and membrane associated non-receptor tyrosine kinases^{11,12}. These kinases are now thought to phosphorylate other proteins such as PLC γ (ref. 13) and c-Raf¹⁴ on their tyrosine residues leading to their activation.

Receptor tyrosine kinases and their growth factors in cancer

There are as many as 14 types of tyrosine kinase growth factor receptors, as indicated in Table 1. Some of these receptors have been shown to play a critical role in the induction of cancer. The mechanism by which these receptors could contribute to tumourigenesis include overexpression of the receptors or their ligands and mutation of the receptors resulting in abnormal activity even in the absence of the ligand.




Figure 2. Mechanisms of action of peptide growth factors.

Table 1. Tyrosine kinase membrane receptors and their ligands⁵⁹

Family	Growth factor receptors	Growth factors
1	Epidermal growth factor receptor (EGFR; HER1)	EGF; TGF α , betacellulin, HB-EGF, Amphiregulin
	c-erbB2 (HER2)	None identified
	c-erbB3 (HER3)	Neuregulin
	c-erbB4 (HER4)	Neuregulin
2	Insulin receptor	Insulin
	Insulin-like growth factor receptor 1 (IGF-1R)	Insulin like growth factor 1 and 2 (IGF-I, IGF-II)
	Insulin-like growth factor receptor 2/Mannose-6-phosphate receptor (IGF-II R/M-6-P receptor)	
	Insulin receptor related kinase (IRRK)	
3	Platelet-derived growth factor receptor (PDGFR)	Platelet derived growth factor (PDGF)
	Colony-stimulating factor-1 receptor (CSF-1R) (c-Fms)	Colony Stimulating Factor-1 (CSF-1)
	Steel receptor (c-Kit)	
	Flk2/Flt3	
4	Fibroblast growth factor receptor 1 (Flg/Cek1)	Acidic FGF
	Fibroblast growth factor receptor 2 (Bek/Cek3/K-Sam)	Basic FGF
	Fibroblast growth factor receptor 3	Int-2
	Fibroblast growth factor receptor 4	Hsu/KFGF
		FGF-5
		FGF-6
		KGF
5	Nerve growth factor receptor (NGFR) (TrkA)	NGF
	BDNF receptor (TrkB)	BDNF
	NT-3-receptor (TrkC)	
6	Vascular endothelial growth factor receptor 1 (Flt1)	VEGF
	Vascular endothelial growth factor receptor 2/Flk1/KDR	
7	Hepatocyte growth factor receptor (HGF-R/Met)	
8	Eph	
	Eck	
	Cek4/Mek4/HEK	
	Cek5	
	Elk/Cek6	
	Cek7	
	Sek/Cek8	
	Cek9	
	Cek10	
	HEK11	
9	Ror1	
	Ror2	
10	Ret	
11	Axl	
12	RYK	
13	DDR	
14	Tie	

Signal transduction of growth factor-growth factor receptor interaction

A schematic view of some of the molecules involved in signal transduction is shown in Figure 3. As seen in the figure, following the binding of the growth factor to its receptor, conformational changes occur leading to dimerization and cross-phosphorylation of the receptors. The activated receptor, then phosphorylates molecules like GRB2 and SOS, which in turn activate the GDP bound Ras, to Ras-GTP, which is the active form of Ras. The signal from the activated Ras is then passed on to Raf, MAPKK and MAPK, the latter translocating to the nucleus wherein it activates transcription factors like Jun and Fos. The transcriptional machinery is activated leading to cell division.

Some receptors like the T-cell receptors (TCR) lack a cytoplasmic tyrosine kinase domain. These molecules signal through their association with one of the non-receptor protein tyrosine kinases like JAK.

Cell cycle and growth factors

For the entry of a quiescent cell from the G_0 phase to G_1 phase, competence factors such as PDGF and FGF are needed. Progression through the G_1 phase of cell cycle requires EGF and IGF-1 (progression factors). Baserga¹⁵ has postulated that the primary function of PDGF, FGF and/or EGF is to induce enough IGF-1 and IGF-1 receptor. The growth factor - growth factor receptor signalling act through the G_1 cyclins, particularly the cyclin D family. The induction of cyclin D-cdk4/6 complex leads to phosphorylation of retinoblastoma (Rb) protein, which

is bound to E2F. Once phosphorylated, the Rb protein lets go the E2F transcription factor, which is then available for the entry of the cell into the S-phase. IGF-1 has been shown to induce cyclin-D1 expression in human osteosarcoma cell line, MG63¹⁶.

Role of growth factors and their receptors in apoptosis

Apoptosis or programmed cell death is an important physiological phenomenon playing crucial role in growth and development of an organism. It also plays an important protective role in DNA damaged cells which fail to have their DNA damage repaired but attempting to enter the cell cycle. By triggering apoptosis, these abnormal cells are destroyed, thereby preventing tumour induction. Conversely, in the absence or inhibition of apoptosis, these cells survive and cumulate more DNA damage, tend to acquire a more aggressive phenotype.

IGF-1 and PDGF have been shown to inhibit apoptosis in fibroblasts deprived of serum, whereas EGF and FGF do not have any protective effect from cell death¹⁷. IGF-1 also has been shown to inhibit apoptosis induced by a monoclonal antibody to EGF receptor in a colon cancer cell line. The IGF-1 receptor was also needed for the protective action, as an antibody to the IGF-1 receptor, blocked the inhibition of apoptosis¹⁸.

Role of EGFR, c-erbB2, c-erbB3, c-erbB4 and their ligands in cancer

EGFR

Human squamous cell carcinomas have been shown to exhibit a combination of the constitutive secretion of TGF α and overexpression of EGFR, resulting in an autocrine loop-promoting growth³. Gastric cancers staining positive for both TGF α and EGFR¹⁹ were found to have a higher bromodeoxyuridine labelling index and poorer prognosis compared to those tumours which were negative for both or one of these molecules. Similar pathways have also been demonstrated in high grade brain tumours²⁰ and lung carcinomas²¹.

Additional evidence for the transforming capabilities of EGF receptor and its ligand TGF α , has come from studies involving transgenic mice. Mice transgenic for TGF α were found to develop breast adenocarcinomas, hepatocellular carcinomas and dramatically accelerated growth of pancreatic tumours²²⁻²⁴. The latter two effects were more pronounced in double transgenic expressing TGF α and c-myc²³.

Gene amplification of EGFR occurs in about 40% of glioblastoma multiforme²⁵, 8-20% of head and neck cancers, 8-14% of oesophageal cancers, 3-6% of gastric




Figure 3. Signalling through tyrosine kinase receptors.

cancers and 2% of breast tumours. Overexpression due to altered transcriptional control occurs in a much larger percentage of tumours, for instance, in 25–61% of bladder, 45% of breast, 58% of lung, and 4% of early and 35% of advanced gastric carcinomas. In general, overexpression of EGFR has been found to be associated with poor prognosis. Overexpression of EGFR in breast tumours has generally been associated with an ER (oestrogen negative) phenotype. EGFR positivity has been associated with short disease free (DFS) and overall survival (OS) in node negative patients²⁶. In addition, Harris *et al.*²⁷ have shown that EGFR status predicts response to tamoxifen (more EGFR negative patients' responded to tamoxifen than the EGFR positive patients).

Deletion-mutant EGF receptors have been identified in glioblastomas of the brain²⁸ and in non-small lung carcinomas²⁹. At least three types of mutants have been reported in brain tumours with the type 1 (loss of exons 2–7) being the most common form seen (17%)²⁸. These mutant receptors have the potential to act as tumour-specific antigens as none of the normal tissues express them and therefore are good targets for monoclonal antibody directed therapy.

c-erbB2

Breast cancer: High levels of c-erbB2 are found in more than 90% of comedo, large cell, ductal carcinoma *in situ*, and in general low or absent levels of expression are seen with other subtypes such as papillary and cribriform tumours *in situ*³⁰. The high levels and high incidence in ductal carcinoma *in situ*, together with the absence of expression in premalignant breast epithelial cells such as atypical ductal hyperplasia, indicate that its expression is an early event in tumourigenesis. In addition, almost all cases of mammary Paget's disease overexpress the protein.

Among the invasive tumours, ductal carcinomas are the types associated with c-erbB2 overexpression whereas the lobular carcinomas are in general negative. In breast carcinomas, the gene is amplified in about 20% of cases, leading to substantial overexpression of the receptor protein³⁰. Such elevated expression is generally associated with poor relapse-free and overall survival in node-positive tumours. In node-negative tumours the results have been variable, with some studies showing an association with poor relapse-free and overall survival³¹ and others showing no significant effect³². One flaw common to some reports is the use of too small a number of cases to detect the predictive power of the effect of overexpression if it is similar to that present in node-positive disease. Most of the larger studies have shown that overexpression of c-erbB2 protein which is inversely related to the presence of oestrogen and progesterone receptors, is associated with inflammatory carcinomas, high tumour grade, lymph node metastasis and poor response to therapy³⁰.

Ovarian cancer: 20–40% of ovarian carcinomas overexpress c-erbB2 protein with gene amplification seen in 0–30% of cases³². Overexpression was associated with poor overall survival³² or poor relapse free and overall survival³³.

Gastric cancer: About 20% of gastric cancers overexpress c-erbB2 protein either due to amplification and/or increased transcription. Controversy exists regarding the significance of overexpression of c-erbB2, with some studies reporting that it is associated with poor prognosis and others showing that it confers a survival advantage. Additional studies would be needed to clarify this controversy.

Bladder cancers: Widely varying levels of overexpression have been reported in bladder cancer, ranging from 2% to 74%. The widely varying incidence could be due to sampling errors, type of tissue used (frozen sections versus formalin-fixed paraffin-embedded sections), the antibody used and the technique and criteria used to define positivity. Moriyama *et al.*³⁴ showed that c-erbB2 overexpression in bladder carcinomas was associated with poorly differentiated grade and invasiveness.

Other tumours: c-erbB2 overexpression has been less frequently observed in colorectal, pancreatic, salivary gland and lung carcinomas³⁰. Kern *et al.*³⁵ reported a reduced overall survival in patients with adenocarcinomas of the lungs which overexpressed c-erbB2 protein.

c-erbB3

The c-erbB3 protein overexpression has been reported in gastrointestinal cancers, breast cancers, bladder cancers, cervical cancers and oral cancers^{36,37}. Most of the studies have not shown any significant prognostic association with overexpression of c-erbB3. Knowlden *et al.*³⁸ showed that c-erbB3 and c-erbB4 expression were associated with estrogen receptor (ER) positivity and patients whose ER positive tumours expressed high levels of c-erbB3 were most likely to benefit from endocrine measures.

c-erbB4

Srinivasan *et al.*³⁹ showed that while 10–20% of adenocarcinomas and astrocytomas overexpress c-erbB4, 40–80% of the adenocarcinomas and 100% of the squamous cell carcinomas showed lack of expression, in their series of cases. Their study also suggested that c-erbB4 was more likely to be associated with better differentiation. In medulloblastomas, a form of brain tumour, expression of c-erbB4 and c-erbB2 was

associated with a aggressive tumour phenotype and a poor prognosis.

Role of IGF-I, IGF-II, IGF-IR and IGF-IIR in cancer

Wilm's tumour

Wilm's tumour is a kidney cancer occurring in children. The Wilm's tumour predisposition gene, WT1, product is a transcriptional factor/regulator. During the normal kidney development, there is an initial high level of expression of IGF-II by the undifferentiated proliferating blastoma but is absent in the epithelial cells of the renal vesicles and the podocyte epithelia. WT1 is not expressed during this phase, but occurs later, with declining levels of IGF-II and IGF-I receptor. Down regulation of WT1 expression or deletion or mutation of the *WT1* gene leads to derepression of IGF-II and IGF-I receptor genes, leading to an inappropriate expression of an autocrine/paracrine pathway involving IGF-II and IGF-I receptor, which in turn can lead to mitogenesis⁴⁰.

IGF's and their receptors have been found to be expressed in a wide range of tumours, including, Wilm's tumour, liver cancer, lung cancer, breast cancer, etc.

Role of PDGF and PDGF-receptors in cancer

PDGF exists as homo or heterodimer of two polypeptides, the A and B chains. Their receptors (PDGFR α and PDGFR β) were found to be expressed in microvascular endothelium. It is likely that PDGF might stimulate angiogenesis both by a direct effect on endothelial cells and by inducing angiogenic factors like VEGF⁴¹.

PDGF and PDGFR have been demonstrated in the tumour cells and in the stromal cells, enabling a potential autocrine or paracrine mode of activation of angiogenesis. PDGFR was also found to be expressed on vascular endothelial cells in breast tumour⁴².

Role of VEGF and VEGF-receptors in cancer

Vascular endothelial growth factor (VEGF) can bind to VEGFR1/Flt-1 or to VEGFR2/Flk-1/KDR. These molecules play an important role in angiogenesis during development, wound healing and in the pathogenesis of tumour neovascularization.

Patients with NSCLC or breast cancer with VEGF positive tumours were found to have a poorer prognosis than those tumours which lacked VEGF^{43,44}. Bellamy *et al.*⁴⁵ have shown that 5/12 human hematopoietic tumour cell lines expressed both VEGF and Flt-1 (VEGFR1) mRNA, indicating a potential autocrine pathway in these tumour cells.

Role of FGF and FGF-receptors in cancer

FGF family of growth factors have diverse actions including their effect on cell proliferation, angiogenesis and neurotrophic effects. In some melanomas and gliomas, FGFs act as autocrine growth factors. Studies have also correlated the presence of the FGFs and their receptors in cancers to more aggressive tumours with a greater tendency to metastasis. FGF2 and FGFR 1 and 2, have been shown to be involved in prostatic cancers⁴⁶. Volm *et al.*⁴⁷ using immunohistochemistry have shown that overexpression of FGFR1 in non-small cell lung carcinoma is associated with poorer prognosis. The FGF family of growth factors and their receptors have been shown to be involved in pancreatic cancers⁴⁸.

Role of RET proto-oncogene in cancer

Patients with multiple endocrine neoplasia 2A (MEN 2A) have missense mutations at the extracellular cysteine-rich domain of c-ret, which leads to constitutive activation of the tyrosine kinase activity or alteration of substrate recognition or both, leading to transformation⁴⁹. MEN 2A syndrome is characterized by bilateral medullary carcinoma of thyroid, pheochromocytoma and hyperparathyroidism.

MEN 2B is associated with a germline point mutation in the c-ret proto-oncogene tyrosine kinase catalytic domain, leading to a methionine to threonine substitution at codon 918 in the kinase domain, which alters the substrate specificity of the protein⁵⁰. MEN 2B is characterized by medullary carcinoma of thyroid, pheochromocytoma, marfanoid body habitus, oral and eye mucosal neuromas and gastrointestinal tract ganglioneuromas. The methionine 918 to threonine mutation seen in MEN 2B is also seen in up to one-third of sporadic medullary carcinoma of thyroid; in a few other sporadic cases, glutamic acid 768 to aspartic acid mutations are seen.

Role of HGF and HGFR/Met in cancer

The hepatocyte growth factor (HGF) is expressed in the stromal cells while its receptor, HGFR/Met, is expressed in a variety of epithelial cells. They are involved in development of organs including lung, kidney, breast particularly with regard to branching morphogenesis and tubulogenesis. They are also necessary for neuronal development, muscle development, hematopoiesis and angiogenesis.

The HGF-HGFR/Met pathway is involved in cancer as well. They promote invasiveness and metastasis of the tumours through rearrangements of the cytoskeleton; by activating cell adhesion molecules and by promoting degradation of extracellular matrix by tumour cells

through induction of synthesis of urokinase-type plasminogen and its receptor. HGF transgenic mice have been shown to develop a wide range of epithelial and mesenchymal cancers like breast cancers, melanoma, fibrosarcoma. In human tumours, HGF-HGFR/Met has been shown to be overexpressed in gastric, liver, colon, lung and thyroid cancers. Overexpression of HGF has been shown to be an independent predictor of poor prognosis in NSCLC. HGF-HGFR/Met also may contribute to B-cell malignancies including large cell lymphomas and myelomas⁵¹.

Hereditary papillary renal carcinoma (HPRC), an autosomal dominant disease with reduced penetrance, is characterized by a predisposition to develop multiple, bilateral papillary renal tumours. Schmidt *et al.*⁵² identified missense mutations located in the tyrosine kinase domain of the *Met* gene in the germline of affected members of HPRC families and in a subset of sporadic papillary renal carcinomas. Three mutations in the *Met* gene were located in codons that are homologous to those in *c-kit* and *Ret* proto-oncogenes that are targets of naturally occurring mutations. Their results suggest that missense mutations located in the *Met* proto-oncogene lead to constitutive activation of the Met protein and papillary renal carcinomas.

Targeting growth factors and their receptors

Several strategies aimed at blocking the mitogenic signalling pathway that is activated following ligand-receptor interactions, are being evaluated. These include growth factor antagonists (pentosan polysulphate), monoclonal antibodies, receptor dimerization inhibitors, protein tyrosine kinase inhibitors (genistein, erbstatin, tyrphostins), antisense oligonucleotides and transcriptional inhibitors⁵³ (Figure 4). Monoclonal antibodies raised against the extracellular domain of the orphan receptors for functional studies can also be used for targeting tumours overexpressing these receptors.

Suramin

This polysulphonated drug inhibits the binding of GF like PDGF, FGF, EGF, TGF α , IGF-1, IGF-2, IL-2 and nerve growth factor to their receptors and can induce disassociation of bound growth factors from their receptors. The drug has shown to have activity against renal cancer, prostate cancer and adrenal cancers.

Monoclonal antibodies to GFR

The introduction of anti-c-erbB2 humanized antibody, trastuzumab, in the treatment of tumours overexpressing c-erbB2, particularly breast cancers is a classic example of taking the advances in the laboratory to the patients'




Figure 4. Targeting growth factors and growth factor receptors.

bedside. The antibody has shown a response of around 15% with a median overall survival rate of 13 months in metastatic breast cancer. Combined use of chemotherapy (anthracyclines or taxanes) with the antibody has shown an improved response rate for the combined approach over chemotherapy alone⁵⁴.

Similar promising data are available from pre-clinical studies using anti-EGFR antibodies.

Tyrosine kinase inhibitors

Specific tyrosine kinase inhibitors are being developed, one such example being the 4-anilinoquinazolines which has been developed as an inhibitor of EGFR tyrosine kinase⁵⁵. Tryphostins specific for the EGFR have been shown to inhibit primary glioblastomas⁵⁶ and prostate cancers⁵⁷. A c-erbB2 specific tyrosine kinase inhibitor, AG825, was found to sensitize c-erbB2 overexpressing tumour cells to chemotherapy⁵⁸.

1. Fantl, W. J., Johnson, D. E. and Williams, L. T., *Annu. Rev. Biochem.*, 1993, 62, 453-481.
2. Sporn, M. B. and Todaro, G. J., *N. Engl. J. Med.*, 1980, 303, 878-880.
3. Reiss, M., Stash, E. B., Vellucci, V. F. and Zhou, Z., *Cancer Res.*, 1991, 51, 6254-6262.
4. Sherman, L., Stocker, K. M., Morrison, R. and Ciment, G., *Development*, 1993, 118, 1313-1326.
5. Wong, S. T. *et al.*, *Cell*, 1989, 56, 495-506.
6. Accili, D. *et al.*, *EMBO J.*, 1989, 8, 2509-2517.
7. Shiang, R. *et al.*, *Cell*, 1994, 78, 335-342.
8. Elder, J. T. *et al.*, *Science*, 1989, 243, 811-814.
9. Bishop, J. M., *Science*, 1987, 235, 305-311.
10. Fearon, E. R. and Vogelstein, B., *Cell*, 1990, 61, 759-767.

11. Bolen, J. B., *Oncogene*, 1993, 8, 2025-2031.
12. Hesketh, R., *The Oncogene Handbook*, Academic Press Ltd, London, 1994, 1st edn.
13. Meisenhelder, J., Suh, P. G., Rhee, S. G. and Hunter, T., *Cell*, 1989, 57, 1109-1122.
14. Morrison, D. K., Kaplan, D. R., Rapp, U. and Roberts, T. M., *Proc. Natl. Acad. Sci. USA*, 1988, 85, 8855-8859.
15. Baserga, R., *Receptor*, 1992, 2, 261-266.
16. Furlanetto, R. W., Harwell, S. E. and Frick, K. K., *Mol. Endocrinol.*, 1994, 8, 510-517.
17. Harrington, E. A., Bennett, M. R., Fanidi, A. and Evan, G. I., *EMBO J.*, 1994, 13, 3286-3295.
18. Wu, X., Fan, Z., Masui, H., Rosen, N. and Mendelson, J., *Proc. Annu. Meeting Am. Assoc. Cancer Res.*, 1994, 35, A16.
19. Yonemura, Y. et al., *Oncology*, 1992, 49, 157-161.
20. Ekstrand, A. J., Sugawa, N., James, C. D. and Collins, V. P., *Proc. Natl. Acad. Sci. USA*, 1992, 89, 4309-4313.
21. Rusch, V. et al., *Cancer Res.*, 1993, 53, 2379-2385.
22. Matsui, Y., Halter, S. A., Holt, J. T., Hogan, B. L. M. and Coffey, R. J., *Cell*, 1990, 61, 1147-1155.
23. Murakami, H., Sanderson, N. D., Nagy, P., Marino, P. A., Merlino, G. and Thorgeirsson, S. S., *Cancer Res.*, 1993, 53, 1719-1723.
24. Sandgren, E. P., Luetke, N. C., Qiu, T. H., Palmiter, R. D., Brinster, R. L. and Lee, D. C., *Mol. Cell. Biol.*, 1993, 13, 320-330.
25. Liberman, T. A. et al., *Nature*, 1985, 313, 144-147.
26. Sainsbury, J. R. C., Farndon, J. R., Needham, G. K., Malcolm, A. J. and Harris, A. L., *Lancet*, 1987, 1, 1398-1402.
27. Harris, A. L., Nicholson, S., Sainsbury, J. R. C., Farndon, J. and Wright, C., *J. Steroid Biochem.*, 1989, 34, 123-131.
28. Humphrey, P. A. et al., *Biochem. Biophys. Res. Commun.*, 1991, 178, 1413-1420.
29. Garcia de Palazzo, I. E., Adams, G. P., Sundareshan, P., Wong, A. J., Testa, J. R., Bigner, D. D. and Weiner, L. M., *Cancer Res.*, 1993, 53, 3217-3220.
30. Lofts, F. J. and Gullick, W. J., *Genes, Oncogenes and Hormones: Advances in Cellular and Molecular Biology of Breast Cancer* (eds Dickson, R. B. and Lippman, M. E.), Kluwer Academic Publishers, Norwell, 1992, 1st edn, pp. 161-179.
31. Gullick, W. J., *Br. Med. Bull.*, 1991, 47, pp. 87-98.
32. Slamon, D. J. et al., *Science*, 1989, 244, 707-712.
33. Berchuck, A. et al., *Cancer Res.*, 1990, 50, 4087-4091.
34. Moriyama, M. et al., *J. Urol.*, 1991, 145, 423-427.
35. Kern, J. A., Schwartz, D. A., Nordberg, J. E., Weiner, D. B., Greene, M. I., Torney, L. and Robinson, R. A., *Cancer Res.*, 1990, 50, 5184-5191.
36. Rajkumar, T. and Gullick, W. J., *Molecular Biology of Cancer* (ed. Waxman, J.), Cambridge University Press, Cambridge, 1996, pp. 3-14.
37. Ibrahim, S. O., Vasstrand, E. N., Liavaag, P. G., Johannessen, A. C. and Lillehaug, J. R., *Anticancer Res.*, 1997, 17, 4539-4546.
38. Knowlden, J. M. et al., *Oncogene*, 1998, 17, 1949-1957.
39. Srinivasan, R., Poulson, R., Hurst, H. C. and Gullick, W. J., *J. Pathol.*, 1998, 185, 236-245.
40. Werner, H. and LeRoith, D., *Adv. Cancer Res.*, 1996, 68, 183-223.
41. Enholm, B. et al., *Oncogene*, 1997, 14, 2475-2483.
42. Bhardwaj, J. B., Klassen, J., Lo, K.-M., Folkman, J. and Hanahan, D., *Science*, 1999, 84, 808-812.
43. Ohta, Y. et al., *Clin. Cancer Res.*, 1996, 2, 1411-1416.
44. Eppenberger, U. et al., *J. Clin. Oncol.*, 1998, 16, 3129-3136.
45. Bellamy, W. T., Richter, L., Fruitiger, Y. and Grogan, T. M., *Cancer Res.*, 1999, 59, 728-733.
46. Giri, D., Ropiquet, F. and Ittmann, M., *Clin. Cancer Res.*, 1999, 5, 1063-1071.
47. Volm, M., Koomagi, R., Mattern, J. and Stammers, G., *Eur. J. Cancer*, 1997, 33, 691-693.
48. Kornmann, M., Beger, H. G. and Korc, M., *Pancreas*, 1998, 17, 169-175.
49. Donis-Keller, H. et al., *Hum. Mol. Genet.*, 1993, 2, 851-855.
50. Hofstra, R. M. W. et al., *Nature*, 1994, 367, 375-379.
51. van der Voort, R., Taher, T. E. I., Derksen, P. W. B., Spaargaren, M., van der Neut, R. and Pals, S. T., *Adv. Cancer Res.*, 2000, 79, 39-90.
52. Schmidt, L. et al., *Nature Genet.*, 1997, 16, 68-73.
53. Lofts, F. J. and Gullick, W. J., *New Molecular Targets for Cancer Chemotherapy* (eds Kerr, D. J. and Workman, P.), CRC Press, Boca Raton, 1994, pp. 45-66.
54. Slamon, D. et al., *Proc. Am. Soc. Clin. Oncol.*, 1998, 17, A377.
55. Wakeling, A. E. et al., *Breast Cancer Res. Treat.*, 1996, 38, 67-73.
56. Penar, P. L., Khoshyomn, S., Bhushan, A. and Tritton, T. R., *Neurosurgery*, 1997, 40, 141-151.
57. Kondapaka, B. S. and Reddy, K. B., *Mol. Cell. Endocrinol.*, 1996, 117, 53-58.
58. Tsai, C. M., Levitzki, A., Wu, L. H., Chang, K. T., Cheng, C. C., Gazit, A. and Perng, R. P., *Cancer Res.*, 1996, 1068-1074.
59. van der Geer, P., Hunter, T. and Lindberg, R. A., *Annu. Rev. Cell Biol.*, 1994, 10, 251-337.